Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers | Zendy

Kirk W. Johnson | Zendy; Ann Neale | Zendy; Allan Gordon | Zendy; Julie M. Roessig | Zendy; Padma Bezwada | Zendy; Sabine Vukelich | Zendy; Ira D. Goldfine | Zendy; Paul Rubin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers

Author(s) -

Kirk W. Johnson,

Ann Neale,

Allan Gordon,

Julie M. Roessig,

Padma Bezwada,

Sabine Vukelich,

Ira D. Goldfine,

Paul Rubin

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-00822

Subject(s) - medicine , insulin , pharmacodynamics , tolerability , endocrinology , insulin receptor , placebo , pharmacokinetics , hypoglycemia , adverse effect , postprandial , insulin resistance , pharmacology , alternative medicine , pathology

XOMA 358 (X358) is a fully human monoclonal antibody to the insulin receptor that acts as a negative allosteric modulator of insulin signaling. It is being developed as a novel treatment of hyperinsulinemic hypoglycemia. This report describes pharmacokinetic (PK) and pharmacodynamic (PD) data from a first-in-human clinical trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research